KYMR

SEC source: 0000950170-24-013482 · ownership.xml · nonDerivative · entry 2

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,107

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-013482 · ownership.xml · nonDerivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 22, 2023 adopted by the reporting person.

SEC source: 0000950170-24-006766 · ownership.xml · derivative · entry 3

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,349

Underlying: Common Stock · 10,000 shares

Expires 2030-07-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023.

F3 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date.

SEC source: 0000950170-24-006766 · ownership.xml · nonDerivative · entry 2

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-24-006766 · ownership.xml · nonDerivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023.

SEC source: 0000921895-24-000071 · form407422010_01092024.xml · derivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,733

Underlying: Common Stock, $0.0001 par value · 52,733 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F10 · derivative.exercise_date: The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

F10 · derivative.expiration_date: The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-24-000071 · form407422010_01092024.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,856

Underlying: Common Stock, $0.0001 par value · 375,856 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F10 · derivative.exercise_date: The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

F10 · derivative.expiration_date: The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-24-000071 · form407422010_01092024.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 550,425

Underlying: Common Stock, $0.0001 par value · 550,425 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F10 · derivative.exercise_date: The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

F10 · derivative.expiration_date: The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000950170-24-002536 · ownership.xml · nonDerivative · entry 1

Chiniara Ellen · CIK 0001398764 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,205

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $22.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-000386 · ownership.xml · derivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519,972

Underlying: Common Stock · 9,000 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000950170-24-000386 · ownership.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 615,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000921895-23-002475 · form407422010_11062023.xml · nonDerivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,632

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-23-002475 · form407422010_11062023.xml · nonDerivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,104,075

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-23-002475 · form407422010_11062023.xml · nonDerivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,656,191

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000950170-23-059580 · ownership.xml · derivative · entry 4

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 528,972

Underlying: Common Stock · 17,632 shares

Expires 2029-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000950170-23-059580 · ownership.xml · derivative · entry 3

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,368 shares

Expires 2029-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000950170-23-059580 · ownership.xml · nonDerivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 606,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-23-059580 · ownership.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 588,938

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000921895-23-002475 · form407422010_11062023.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 284,526

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-23-002475 · form407422010_11062023.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,020,367

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-23-002475 · form407422010_11062023.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,552,306

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000950170-23-039894 · ownership.xml · derivative · entry 2

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,368

Underlying: Common Stock · 12,000 shares

Expires 2029-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares underlying this stock option vested in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000950170-23-039894 · ownership.xml · nonDerivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 586,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes 870 shares acquired under the Registrant's employee stock purchase plan on May 31, 2023.

SEC source: 0000921895-23-001547 · form407422kymr_06202023.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · Director · See Remarks and Footnotes

BVF I GP LLC · CIK 0001803805 · Director · See Remarks and Footnotes

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · Director · See Remarks and Footnotes

BVF II GP LLC · CIK 0001803806 · Director · See Remarks and Footnotes

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · Director · See Remarks and Footnotes

BVF Partners OS Ltd. · CIK 0001660684 · Director · See Remarks and Footnotes

BVF GP HOLDINGS LLC · CIK 0001803809 · Director · See Remarks and Footnotes

BVF INC/IL · CIK 0001056807 · Director · See Remarks and Footnotes

LAMPERT MARK N · CIK 0001233840 · Director · See Remarks and Footnotes

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 12,000

Underlying: Common Stock, $0.0001 par value · 12,000 shares

Expires 2033-06-14

F5 · security: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F6 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F5 · ownership.direct: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

F5 · ownership.nature: Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

SEC source: 0000899243-23-015965 · doc4.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015969 · doc4.xml · derivative · entry 1

Sandor Victor · CIK 0001620368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015967 · doc4.xml · derivative · entry 1

Morgan Leigh · CIK 0001935887 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015968 · doc4.xml · derivative · entry 1

Ridloff Elena · CIK 0001772518 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015966 · doc4.xml · derivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-23-015963 · doc4.xml · derivative · entry 1

Horobin Joanna · CIK 0001560959 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015964 · doc4.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015961 · doc4.xml · derivative · entry 1

Esposito Pamela · CIK 0001744425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-015960 · doc4.xml · derivative · entry 1

Hrustanovic Gorjan · CIK 0001821194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: The Reporting Person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000950170-23-025989 · ownership.xml · derivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,899

Underlying: Common Stock · 10,000 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000950170-23-025989 · ownership.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-23-023515 · ownership.xml · derivative · entry 2

Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2023-05-22

F2 · derivative.exercise_date: 25% of the shares underlying this stock option shall vest on May 22, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000950170-23-023515 · ownership.xml · nonDerivative · entry 1

Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,333

F1 · shares: Represents restricted stock units ("RSUs") Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following May 22, 2023, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-23-006981 · doc4.xml · nonDerivative · entry 3

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,709

F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-006981 · doc4.xml · nonDerivative · entry 2

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,006

F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-006984 · doc4.xml · nonDerivative · entry 3

Caughey Elaine · CIK 0001868668 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,986

F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-006984 · doc4.xml · nonDerivative · entry 2

Caughey Elaine · CIK 0001868668 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,150

F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-006979 · doc4.xml · nonDerivative · entry 3

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,568

F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-006979 · doc4.xml · nonDerivative · entry 2

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,882

F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales were automatic and intended to qualify under Rule 10b5-1.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 to $31.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-006986 · doc4.xml · derivative · entry 1

Mainolfi Nello · CIK 0001821189 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-23-006981 · doc4.xml · derivative · entry 4

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Underlying: Common Stock · 112,500 shares

Expires 2033-02-28

F5 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-23-006981 · doc4.xml · nonDerivative · entry 1

Gollob Jared · CIK 0001821198 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,007

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-23-006984 · doc4.xml · derivative · entry 4

Caughey Elaine · CIK 0001868668 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,338

Underlying: Common Stock · 63,338 shares

Expires 2033-02-28

F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-23-006984 · doc4.xml · nonDerivative · entry 1

Caughey Elaine · CIK 0001868668 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,700

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

F2 · balance_after: This number includes 465 shares acquired under the Registrant's employee stock purchase plan (the "ESPP") on June 1, 2022 and 1,678 shares acquired under the ESPP on December 1, 2022.

SEC source: 0000899243-23-006979 · doc4.xml · derivative · entry 4

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common Stock · 142,500 shares

Expires 2033-02-28

F6 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

SEC source: 0000899243-23-006979 · doc4.xml · nonDerivative · entry 1

Jacobs Bruce N. · CIK 0001821074 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,938

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2023, subject to the reporting person's continued employment through each vesting date.

F2 · balance_after: This number includes 909 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022.